RecruitingEarly Phase 1NCT06920433

UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus

Studying Autosomal systemic lupus erythematosus

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Zhejiang University
Intervention: UCAR T-cell group(biological)
Enrollment: 18 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2027

Study locations (1)

The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China

Collaborators

Shanghai Xiniao Biotech Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06920433 on ClinicalTrials.gov

Other trials for Autosomal systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Autosomal systemic lupus erythematosus →

← Back to all trials